• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

3.530 -0.600 (-14.53%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,812,065
Open 4.380
Bid (Size) 3.650 (5,700)
Ask (Size) 3.730 (5,000)
Prev. Close 4.130
Today's Range 3.500 - 4.470
52wk Range 3.150 - 7.440
Shares Outstanding 62,064,270
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks have an unusual volume in today's session ↗
October 14, 2026
Via Chartmill
News headline image
Zura Bio to Participate in the Cantor Global Healthcare Conference
August 31, 2026
From Zura Bio Limited
Via Business Wire

Performance

52-Week Range 52.6% below 52-week high
3.530
3.1552W Low 7.4452W High
1 Week 21.0% below 1-week high
3.501W Low 4.471W High

Zura Bio Limited - Class A Ordinary shares (ZURA) traded between $3.15 and $7.44 over the past 52 weeks and last traded at $3.53, 52.6% below its 52-week high. Over the past week it ranged between $3.50 and $4.47.

Past 12 Months
-9.0%
-21.7%
-33.3%
-36.1%
-36.4%
+6.0%
1W -$0.35
1M -$0.98
3M -$1.76
6M -$1.99
YTD -$2.02
1Y +$0.20

ZURA was +6.0% over the past year, -36.1% over six months, -36.4% year to date, -9.0% in the last week.

12 Months vs Market
ZURA
+6.0%
DIA
+12.5%
SPY
+13.8%
QQQ
+15.2%
IWM
+12.0%

Over the past 12 months ZURA returned +6.0% versus DIA (Dow) +12.5%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 3.85× 3-mo avg
Today 8,812,065 3-mo avg 2.3M
1W
5.2M
1M
4.1M
3M
2.3M
6M
1.7M
YTD
1.3M
1Y
1.2M

ZURA most recently traded 8,812,065 shares against a 3-month average daily volume of 2.3M.

More News

Read More
News headline image
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
August 11, 2026
From Zura Bio Limited
Via Business Wire
ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance ↗
May 07, 2026
Via Chartmill
News headline image
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy ↗
July 08, 2026
Via Benzinga
News headline image
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
June 29, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
May 13, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
May 07, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
March 19, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
March 05, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in Upcoming Investor Conferences
March 02, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 27, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
February 25, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
February 25, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
February 25, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
February 25, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
February 24, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
February 23, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 04, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
January 21, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Business Updates and Outlook for 2026
January 12, 2026
From Zura Bio Limited
Via Business Wire
News headline image
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
November 13, 2025
From Zura Bio Limited
Via Business Wire

Frequently Asked Questions

Is Zura Bio Limited - Class A Ordinary shares publicly traded?
Yes, Zura Bio Limited - Class A Ordinary shares is publicly traded.
What exchange does Zura Bio Limited - Class A Ordinary shares trade on?
Zura Bio Limited - Class A Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Zura Bio Limited - Class A Ordinary shares?
The ticker symbol for Zura Bio Limited - Class A Ordinary shares is ZURA on the Nasdaq Stock Market
What is the current price of Zura Bio Limited - Class A Ordinary shares?
The current price of Zura Bio Limited - Class A Ordinary shares is 3.530
When was Zura Bio Limited - Class A Ordinary shares last traded?
The last trade of Zura Bio Limited - Class A Ordinary shares was at 10/22/26 04:00 PM ET
What is the market capitalization of Zura Bio Limited - Class A Ordinary shares?
The market capitalization of Zura Bio Limited - Class A Ordinary shares is 219.09M
How many shares of Zura Bio Limited - Class A Ordinary shares are outstanding?
Zura Bio Limited - Class A Ordinary shares has 219M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap